Mechanism

How it works

TB-500 works primarily by upregulating actin, a protein critical for cell migration, proliferation, and wound healing. It binds to actin monomers, promoting the formation of new blood vessels (angiogenesis), reducing inflammatory cytokines, and facilitating the recruitment of stem cells and progenitor cells to sites of injury. It also modulates integrin expression on cell surfaces, enhancing cell motility and tissue remodeling.

Reported in research

Benefits

Accelerated healing of muscle, tendon, and ligament injuries
Reduced inflammation at injury sites
Promoted angiogenesis and improved local blood flow to damaged tissue
Enhanced flexibility and reduced scar tissue formation

Context, not a prescription

Dosing

Typical range: 2-5 mg twice weekly (loading phase), then 2-5 mg every 1-2 weeks (maintenance) (Subcutaneous, Intramuscular)
Cycle length: 4-8 weeks loading, followed by maintenance as needed
Half-life: ~4-6 hours (estimated; not well-characterized in humans)

Safety

Side effects & contraindications

Possible side effects

Mild fatigue or lethargy, especially shortly after injection
Transient nausea reported anecdotally
Mild headache in some users
Potential for theoretical tumor growth promotion (unconfirmed in healthy subjects)

Contraindications

Active cancer or history of cancer (theoretical concern regarding angiogenesis and tumor support)
Pregnancy or breastfeeding (insufficient safety data)
Known hypersensitivity to Thymosin Beta-4 or excipients in the formulation

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

You may notice reduced pain and stiffness at injury sites, faster return to normal range of motion, and quicker recovery from training sessions. Some report improved skin quality as a secondary benefit.

How it works

Imagine your body's healing system is like a fire department. An injury is the fire. TB-500 is like pulling the alarm and also calling in extra fire trucks from neighboring towns — it dramatically speeds up the response and brings more resources to put out the fire and repair the damage.

After injection, TB-500 travels through the bloodstream and concentrates at areas of inflammation or injury. It helps new blood vessels form so the tissue gets more oxygen and nutrients, and it tells cells to migrate into the damaged area to rebuild it.

What to expect

Most users report noticing reduced soreness and improved mobility within 1-2 weeks of starting a loading protocol, with more significant tissue repair benefits appearing over 4-6 weeks.

Week 1: Initial injections; some users notice mild fatigue post-injection. Anti-inflammatory effects may begin reducing acute pain and swelling.
Weeks 2-4: Gradual improvement in range of motion and reduced soreness at injury sites. Angiogenesis and cell migration are actively occurring. Most users notice meaningful improvement in chronic injuries during this period.
Weeks 4-8: Continued tissue remodeling. Tendon, ligament, and muscle injuries show more complete healing. Some users transition to a lower maintenance dose at this stage.

Good to know

Start with a lower dose (2 mg) to assess tolerance before moving to higher doses
Always use bacteriostatic water to reconstitute and maintain sterile injection technique
Consult a physician before use, especially if you have any underlying health conditions

Staying safe

Feeling tired or sluggish for a few hours after injection
Mild nausea, usually short-lived
Slight redness or irritation at the injection site

Avoid if you have:

Anyone with a history of cancer
Pregnant or breastfeeding individuals
Competitive athletes subject to WADA drug testing

Overview

Physiologically, users and animal subjects exhibit reduced edema and inflammatory cell infiltration, increased capillary density at injury sites, improved extracellular matrix organization (reduced disorganized scar collagen), enhanced satellite cell activation in muscle tissue, and measurable improvements in tissue tensile strength. In cardiac animal models, TB-500 has demonstrated reduced infarct size and improved ejection fraction post-ischemia.

How it works

Think of cellular actin dynamics as a city's traffic system. TB-500 acts as both a traffic controller and infrastructure engineer — it sequesters free actin monomers (managing traffic flow), triggers VEGF-mediated angiogenesis (builds new roads), suppresses NFκB signaling (reduces traffic accidents/inflammation), and activates ILK/Akt survival pathways (strengthens the bridges). The net result is a highly coordinated, multi-modal tissue reconstruction program.

Following subcutaneous or intramuscular administration, TB-500 achieves systemic distribution with preferential accumulation at sites of tissue damage, likely due to local actin concentration gradients and inflammatory chemokine signaling. Its short half-life (~4-6 hours estimated) necessitates twice-weekly dosing during loading phases. Angiogenic effects, detectable histologically in animal models within 3-5 days, contribute to improved oxygen and nutrient delivery. Stem cell recruitment via SDF-1/CXCR4 axis enhancement has been observed in preclinical cardiac models. Immunomodulatory effects include M2 macrophage polarization promotion, shifting the local microenvironment from pro-inflammatory to pro-regenerative.

Onset & timeline

Pharmacokinetically, peak plasma concentrations are reached within 30-60 minutes of subcutaneous injection. Anti-inflammatory and pro-migratory signaling effects begin within hours. Histologically measurable angiogenesis and cellular proliferation at injury sites are detectable in animal models within 3-7 days. Clinically perceptible tissue repair benefits in human anecdotal reports typically emerge at 1-2 weeks, with structural tissue remodeling requiring 4-8+ weeks.

Days 1-3: Initial subcutaneous administration leads to peak plasma concentrations within 30-60 minutes. NFκB suppression and anti-inflammatory cytokine modulation begin within hours. Early reduction in prostaglandin-mediated pain signaling may be perceptible. Actin sequestration promotes initial cell migration signals at injury sites.
Weeks 1-2: VEGF upregulation drives measurable neovascularization in animal models by day 5-7. Satellite cell activation and myoblast proliferation are underway in muscle tissue. Collagen fiber organization at tendon injury sites begins improving. Users typically report reduced acute pain and early improvements in range of motion.
Weeks 2-8: Progressive extracellular matrix remodeling with improved collagen cross-linking and reduced disorganized scar tissue. Continued angiogenesis improves metabolic support of healing tissue. Integrin-linked kinase/Akt pathway activation supports sustained cellular survival signals. In cardiac animal models, functional improvements are measurable by week 4. Maintenance dosing (2-5 mg biweekly) sustains regenerative signaling during this phase.

Getting the most from it

Conduct baseline health screening including cancer markers before initiating use in at-risk individuals
Maintain cold chain integrity during storage; use reconstituted peptide within 28 days and verify pH and clarity before injection
Source peptides from vendors with third-party HPLC and mass spectrometry purity verification to ensure peptide integrity and absence of contaminants

Common side effects

Transient fatigue and mild lethargy lasting 1-4 hours post-injection, possibly related to acute cytokine modulation
Injection site reactions including mild erythema, swelling, or pruritus

Mechanism of action

TB-500 (the Ac-LKKTETQ fragment of Thymosin Beta-4) exerts its regenerative effects primarily through sequestration of G-actin monomers, thereby regulating actin dynamics and facilitating lamellipodia formation essential for cell migration. It promotes angiogenesis via upregulation of VEGF and HIF-1α signaling pathways, and modulates the inflammatory cascade by downregulating NFκB-mediated pro-inflammatory cytokine production (IL-1β, TNF-α). TB-500 also activates integrin-linked kinase (ILK) pathways, stimulating Akt/PKB phosphorylation which promotes cardiomyocyte and stem cell survival, proliferation, and differentiation. The peptide's extracellular matrix interactions further enhance MMP-mediated tissue remodeling.

Following subcutaneous or intramuscular administration, TB-500 achieves systemic distribution with preferential accumulation at sites of tissue damage, likely due to local actin concentration gradients and inflammatory chemokine signaling. Its short half-life (~4-6 hours estimated) necessitates twice-weekly dosing during loading phases. Angiogenic effects, detectable histologically in animal models within 3-5 days, contribute to improved oxygen and nutrient delivery. Stem cell recruitment via SDF-1/CXCR4 axis enhancement has been observed in preclinical cardiac models. Immunomodulatory effects include M2 macrophage polarization promotion, shifting the local microenvironment from pro-inflammatory to pro-regenerative.

Pharmacodynamics

Pharmacokinetically, peak plasma concentrations are reached within 30-60 minutes of subcutaneous injection. Anti-inflammatory and pro-migratory signaling effects begin within hours. Histologically measurable angiogenesis and cellular proliferation at injury sites are detectable in animal models within 3-7 days. Clinically perceptible tissue repair benefits in human anecdotal reports typically emerge at 1-2 weeks, with structural tissue remodeling requiring 4-8+ weeks.

Physiologically, users and animal subjects exhibit reduced edema and inflammatory cell infiltration, increased capillary density at injury sites, improved extracellular matrix organization (reduced disorganized scar collagen), enhanced satellite cell activation in muscle tissue, and measurable improvements in tissue tensile strength. In cardiac animal models, TB-500 has demonstrated reduced infarct size and improved ejection fraction post-ischemia.

Timeline

Days 1-3: Initial subcutaneous administration leads to peak plasma concentrations within 30-60 minutes. NFκB suppression and anti-inflammatory cytokine modulation begin within hours. Early reduction in prostaglandin-mediated pain signaling may be perceptible. Actin sequestration promotes initial cell migration signals at injury sites.
Weeks 1-2: VEGF upregulation drives measurable neovascularization in animal models by day 5-7. Satellite cell activation and myoblast proliferation are underway in muscle tissue. Collagen fiber organization at tendon injury sites begins improving. Users typically report reduced acute pain and early improvements in range of motion.
Weeks 2-8: Progressive extracellular matrix remodeling with improved collagen cross-linking and reduced disorganized scar tissue. Continued angiogenesis improves metabolic support of healing tissue. Integrin-linked kinase/Akt pathway activation supports sustained cellular survival signals. In cardiac animal models, functional improvements are measurable by week 4. Maintenance dosing (2-5 mg biweekly) sustains regenerative signaling during this phase.

Comparisons

TB-500 — effectiveness High, safety Moderate, cost $$, Medium to use
BPC-157 — effectiveness High, safety Good, cost $$, Medium to use

Adverse effects

Common:

Transient fatigue and mild lethargy lasting 1-4 hours post-injection, possibly related to acute cytokine modulation
Injection site reactions including mild erythema, swelling, or pruritus

Rare:

Theoretical concern: promotion of pre-existing occult tumor angiogenesis — no confirmed cases in healthy research subjects but represents a mechanistically plausible risk given VEGF upregulation
Rare anecdotal reports of transient nausea and headache (incidence unknown; not characterized in controlled trials)

Contraindications & risk mitigation

Contraindicated in:

Individuals with active malignancy or history of cancer: VEGF-mediated angiogenesis could theoretically support tumor vascularity
Patients with active autoimmune conditions where immunomodulation may produce unpredictable outcomes
Individuals with hypercoagulable states: angiogenesis and endothelial activation may theoretically affect thrombotic risk

Conduct baseline health screening including cancer markers before initiating use in at-risk individuals
Maintain cold chain integrity during storage; use reconstituted peptide within 28 days and verify pH and clarity before injection
Source peptides from vendors with third-party HPLC and mass spectrometry purity verification to ensure peptide integrity and absence of contaminants

Qué hace

You may notice reduced pain and stiffness at injury sites, faster return to normal range of motion, and quicker recovery from training sessions. Some report improved skin quality as a secondary benefit.

Cómo funciona

Imagine your body's healing system is like a fire department. An injury is the fire. TB-500 is like pulling the alarm and also calling in extra fire trucks from neighboring towns — it dramatically speeds up the response and brings more resources to put out the fire and repair the damage.

After injection, TB-500 travels through the bloodstream and concentrates at areas of inflammation or injury. It helps new blood vessels form so the tissue gets more oxygen and nutrients, and it tells cells to migrate into the damaged area to rebuild it.

Qué esperar

Most users report noticing reduced soreness and improved mobility within 1-2 weeks of starting a loading protocol, with more significant tissue repair benefits appearing over 4-6 weeks.

Week 1: Initial injections; some users notice mild fatigue post-injection. Anti-inflammatory effects may begin reducing acute pain and swelling.
Weeks 2-4: Gradual improvement in range of motion and reduced soreness at injury sites. Angiogenesis and cell migration are actively occurring. Most users notice meaningful improvement in chronic injuries during this period.
Weeks 4-8: Continued tissue remodeling. Tendon, ligament, and muscle injuries show more complete healing. Some users transition to a lower maintenance dose at this stage.

Bueno saber

Start with a lower dose (2 mg) to assess tolerance before moving to higher doses
Always use bacteriostatic water to reconstitute and maintain sterile injection technique
Consult a physician before use, especially if you have any underlying health conditions

Manteniéndose seguro

Feeling tired or sluggish for a few hours after injection
Mild nausea, usually short-lived
Slight redness or irritation at the injection site

Evitar si tienes:

Anyone with a history of cancer
Pregnant or breastfeeding individuals
Competitive athletes subject to WADA drug testing

Descripción general

Physiologically, users and animal subjects exhibit reduced edema and inflammatory cell infiltration, increased capillary density at injury sites, improved extracellular matrix organization (reduced disorganized scar collagen), enhanced satellite cell activation in muscle tissue, and measurable improvements in tissue tensile strength. In cardiac animal models, TB-500 has demonstrated reduced infarct size and improved ejection fraction post-ischemia.

Cómo funciona

Think of cellular actin dynamics as a city's traffic system. TB-500 acts as both a traffic controller and infrastructure engineer — it sequesters free actin monomers (managing traffic flow), triggers VEGF-mediated angiogenesis (builds new roads), suppresses NFκB signaling (reduces traffic accidents/inflammation), and activates ILK/Akt survival pathways (strengthens the bridges). The net result is a highly coordinated, multi-modal tissue reconstruction program.

Following subcutaneous or intramuscular administration, TB-500 achieves systemic distribution with preferential accumulation at sites of tissue damage, likely due to local actin concentration gradients and inflammatory chemokine signaling. Its short half-life (~4-6 hours estimated) necessitates twice-weekly dosing during loading phases. Angiogenic effects, detectable histologically in animal models within 3-5 days, contribute to improved oxygen and nutrient delivery. Stem cell recruitment via SDF-1/CXCR4 axis enhancement has been observed in preclinical cardiac models. Immunomodulatory effects include M2 macrophage polarization promotion, shifting the local microenvironment from pro-inflammatory to pro-regenerative.

Inicio y cronología

Pharmacokinetically, peak plasma concentrations are reached within 30-60 minutes of subcutaneous injection. Anti-inflammatory and pro-migratory signaling effects begin within hours. Histologically measurable angiogenesis and cellular proliferation at injury sites are detectable in animal models within 3-7 days. Clinically perceptible tissue repair benefits in human anecdotal reports typically emerge at 1-2 weeks, with structural tissue remodeling requiring 4-8+ weeks.

Days 1-3: Initial subcutaneous administration leads to peak plasma concentrations within 30-60 minutes. NFκB suppression and anti-inflammatory cytokine modulation begin within hours. Early reduction in prostaglandin-mediated pain signaling may be perceptible. Actin sequestration promotes initial cell migration signals at injury sites.
Weeks 1-2: VEGF upregulation drives measurable neovascularization in animal models by day 5-7. Satellite cell activation and myoblast proliferation are underway in muscle tissue. Collagen fiber organization at tendon injury sites begins improving. Users typically report reduced acute pain and early improvements in range of motion.
Weeks 2-8: Progressive extracellular matrix remodeling with improved collagen cross-linking and reduced disorganized scar tissue. Continued angiogenesis improves metabolic support of healing tissue. Integrin-linked kinase/Akt pathway activation supports sustained cellular survival signals. In cardiac animal models, functional improvements are measurable by week 4. Maintenance dosing (2-5 mg biweekly) sustains regenerative signaling during this phase.

Cómo aprovecharlo al máximo

Conduct baseline health screening including cancer markers before initiating use in at-risk individuals
Maintain cold chain integrity during storage; use reconstituted peptide within 28 days and verify pH and clarity before injection
Source peptides from vendors with third-party HPLC and mass spectrometry purity verification to ensure peptide integrity and absence of contaminants

Efectos secundarios comunes

Transient fatigue and mild lethargy lasting 1-4 hours post-injection, possibly related to acute cytokine modulation
Injection site reactions including mild erythema, swelling, or pruritus

Mecanismo de acción

TB-500 (the Ac-LKKTETQ fragment of Thymosin Beta-4) exerts its regenerative effects primarily through sequestration of G-actin monomers, thereby regulating actin dynamics and facilitating lamellipodia formation essential for cell migration. It promotes angiogenesis via upregulation of VEGF and HIF-1α signaling pathways, and modulates the inflammatory cascade by downregulating NFκB-mediated pro-inflammatory cytokine production (IL-1β, TNF-α). TB-500 also activates integrin-linked kinase (ILK) pathways, stimulating Akt/PKB phosphorylation which promotes cardiomyocyte and stem cell survival, proliferation, and differentiation. The peptide's extracellular matrix interactions further enhance MMP-mediated tissue remodeling.

Following subcutaneous or intramuscular administration, TB-500 achieves systemic distribution with preferential accumulation at sites of tissue damage, likely due to local actin concentration gradients and inflammatory chemokine signaling. Its short half-life (~4-6 hours estimated) necessitates twice-weekly dosing during loading phases. Angiogenic effects, detectable histologically in animal models within 3-5 days, contribute to improved oxygen and nutrient delivery. Stem cell recruitment via SDF-1/CXCR4 axis enhancement has been observed in preclinical cardiac models. Immunomodulatory effects include M2 macrophage polarization promotion, shifting the local microenvironment from pro-inflammatory to pro-regenerative.

Farmacodinamia

Pharmacokinetically, peak plasma concentrations are reached within 30-60 minutes of subcutaneous injection. Anti-inflammatory and pro-migratory signaling effects begin within hours. Histologically measurable angiogenesis and cellular proliferation at injury sites are detectable in animal models within 3-7 days. Clinically perceptible tissue repair benefits in human anecdotal reports typically emerge at 1-2 weeks, with structural tissue remodeling requiring 4-8+ weeks.

Physiologically, users and animal subjects exhibit reduced edema and inflammatory cell infiltration, increased capillary density at injury sites, improved extracellular matrix organization (reduced disorganized scar collagen), enhanced satellite cell activation in muscle tissue, and measurable improvements in tissue tensile strength. In cardiac animal models, TB-500 has demonstrated reduced infarct size and improved ejection fraction post-ischemia.

Cronología

Days 1-3: Initial subcutaneous administration leads to peak plasma concentrations within 30-60 minutes. NFκB suppression and anti-inflammatory cytokine modulation begin within hours. Early reduction in prostaglandin-mediated pain signaling may be perceptible. Actin sequestration promotes initial cell migration signals at injury sites.
Weeks 1-2: VEGF upregulation drives measurable neovascularization in animal models by day 5-7. Satellite cell activation and myoblast proliferation are underway in muscle tissue. Collagen fiber organization at tendon injury sites begins improving. Users typically report reduced acute pain and early improvements in range of motion.
Weeks 2-8: Progressive extracellular matrix remodeling with improved collagen cross-linking and reduced disorganized scar tissue. Continued angiogenesis improves metabolic support of healing tissue. Integrin-linked kinase/Akt pathway activation supports sustained cellular survival signals. In cardiac animal models, functional improvements are measurable by week 4. Maintenance dosing (2-5 mg biweekly) sustains regenerative signaling during this phase.

Comparaciones

TB-500 — efectividad High, seguridad Moderate, costo $$, Medium de usar
BPC-157 — efectividad High, seguridad Good, costo $$, Medium de usar

Efectos adversos

Comunes:

Transient fatigue and mild lethargy lasting 1-4 hours post-injection, possibly related to acute cytokine modulation
Injection site reactions including mild erythema, swelling, or pruritus

Raros:

Theoretical concern: promotion of pre-existing occult tumor angiogenesis — no confirmed cases in healthy research subjects but represents a mechanistically plausible risk given VEGF upregulation
Rare anecdotal reports of transient nausea and headache (incidence unknown; not characterized in controlled trials)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with active malignancy or history of cancer: VEGF-mediated angiogenesis could theoretically support tumor vascularity
Patients with active autoimmune conditions where immunomodulation may produce unpredictable outcomes
Individuals with hypercoagulable states: angiogenesis and endothelial activation may theoretically affect thrombotic risk

Conduct baseline health screening including cancer markers before initiating use in at-risk individuals
Maintain cold chain integrity during storage; use reconstituted peptide within 28 days and verify pH and clarity before injection
Source peptides from vendors with third-party HPLC and mass spectrometry purity verification to ensure peptide integrity and absence of contaminants

Reference data

Specifications

Molecular formula: C212H350N56O78S (Thymosin Beta-4 full peptide; TB-500 is the Ac-LKKTETQ fragment region)
Molecular weight: ~4963 Da (Thymosin Beta-4); TB-500 fragment ~895 Da
Half-life: ~4-6 hours (estimated; not well-characterized in humans)
Route: Subcutaneous, Intramuscular
Cycle length: 4-8 weeks loading, followed by maintenance as needed
Storage: Store lyophilized powder at 2–8°C (refrigerated). After reconstitution with bacteriostatic water, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles. Keep away from light.
Legal status: Not approved by the FDA for human therapeutic use; classified as a research chemical in the United States. Banned by WADA for use in competitive sports. Legal status varies by country.

FAQ

Common questions

What is the mechanistic difference between TB-500 and full-length Thymosin Beta-4?

TB-500 is specifically the Ac-LKKTETQ fragment (amino acids 17-23) of Thymosin Beta-4, which represents the primary actin-binding domain responsible for G-actin sequestration and cell migration promotion. Full-length Tβ4 additionally has N-terminal domain functions including nuclear localization and distinct signaling roles. In practice, the fragment is believed to recapitulate most of the tissue repair and anti-inflammatory benefits, though rigorous head-to-head comparisons in humans are lacking.

Is there evidence supporting TB-500 use in cardiac repair?

Preclinical animal studies (rat and mouse myocardial infarction models) published in journals including Nature Medicine and Circulation Research have shown that Thymosin Beta-4 reduces infarct size, promotes cardiomyocyte survival via Akt activation, and stimulates epicardial progenitor cell differentiation. These findings are compelling but have not yet been translated to controlled human clinical trials for cardiac applications.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for TB-500 is rated as Animal data. Research is based primarily on animal models.

1. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (2004) — Nature (doi:10.1038/nature02910)
2. Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization (2007) — Nature (doi:10.1038/nature05767)
3. Thymosin beta4 and its role in tissue repair and regeneration (2012) — Annals of the New York Academy of Sciences, 1269:32-37
4. The actin-sequestering protein thymosin-beta4 is a novel inhibitor of activation of antigen-specific T lymphocytes (2000) — Journal of Immunology

Explore

Often discussed alongside

BPC-157 · healing GHK-Cu · skin IGF-1 LR3 · growth CJC-1295 · growth